The FDA has approved Kcentra, a product made from pooled plasma, for the urgent reversal of anticoagulation in adults with acute major bleeding who received a vitamin K antagonist.

Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it has re-launched the Venture catheter, a deflectable-tip catheter used to provide guidewire directional control in challenging coronary and peripheral interventional procedures. The device is available immediately in the United States and expected to become available in select international markets over the next few months.

If a picture is worth a thousand words, how much is a video of still images from previous conference events accompanied by a high-power drum solo worth? A promotion for the Transcatheter Cardiovascular Therapeutics 25th scientific sessions appears to be betting a lot.

CVRx, Inc., a private medical device company, received Food and Drug Administration (FDA) investigational device exemption (IDE) approval, allowing the company to proceed with its hypertension study.

The European Heart Rhythm Association (EHRA) has produced a practical guide to help physicians care for atrial fibrillation patients on new oral anticoagulants. The project includes educational materials available on a website that will be updated as new information becomes available.

Anne M. Gillis, MD, president of the Heart Rhythm Society and a professor at the University of Calgary, will co-chair a joint session on clinical registries on May 9 at Heart Rhythm 2013 in Denver. In a Q&A with Cardiovascular Business, she discussed the evolution of joint sessions and other program details.

Denying reimbursement for the use of thrombectomy devices in stroke patients who are ineligible for intravenous tissue-type plasminogen activator (t-PA) treatment would be unfair and may lead to poor outcomes, according to IMS III researchers.

Patients with atrioventricular block and mild to moderate heart failure who were randomized in the BLOCK HF trial to biventricular pacing as a whole had better outcomes than counterparts who received conventional right ventricular pacing.